Transcatheter Aortic Valve Replacement (TAVR) Clinical Trial
— TAVR-PTOfficial title:
Intensive Versus Usual Home-based Physical Therapy to Promote Functional Recovery After Transcatheter Aortic Valve Replacement (TAVR): A Pilot Randomized Trial
Verified date | January 2017 |
Source | New York University School of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary purpose of this this randomized interventional study is to determine if increased level of home-based rehabilitation coupled with a pre-TAVR consultation visit in transcatheter aortic valve replacement patients will improve functional status and quality of life and will decrease hospital readmission.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 2017 |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 75 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of severe aortic stenosis (AS) as determined by echocardiography, who are deemed eligible for TAVR by the NYULMC Heart Valve Team Exclusion Criteria: - Decisional impairment as assessed by the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC) - Non-English/non-Spanish speaking. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
New York University School of Medicine |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in level of Activity measured by activity monitor called the ActiGraph wGT3X-BT. | Baseline, 2 Weeks | ||
Primary | Change in self-perceived physical health | Baseline, 2 Weeks | ||
Primary | Change in Independence in activities of daily living (ADLs). | Baseline, 2 Weeks | ||
Secondary | Reduction in hospital readmissions following intensive home-based physical therapy reduces | Baseline, 2 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05283356 -
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
|
Phase 4 | |
Recruiting |
NCT06412354 -
EasyCrossTM Device-Self-centering Catheter
|
N/A |